MindRank Pharma to Attend the 43rd J.P. Morgan Healthcare Conference and Biotech Showcase™

January 13-16, 2025, the 43rd J.P. Morgan Healthcare Conference and Biotech Showcase™ will be held in"San Francisco, USA"Held."MindRank"Will attend the two major events, and together with leading figures, innovative companies, and investors in the global healthcare industry, explore industry trends and development opportunities, and actively seek diversified cooperation opportunities.

For more information, please visit:

https://www.jpmorgan.com/about-us/events-conferences/health-care-conference

https://informaconnect.com/biotech-showcase/

The annual J.P. Morgan Healthcare Conference isThe largest industry event in the global biopharmaceuticals and health sector,It is also the medical investment and industry cooperation conference with the largest amount of global information. The conference will bring together nearly 50,000 global industry leaders, rapidly growing innovative companies, technology pioneers, and numerous investors to discuss the latest trends and future development directions in the industry.

Biotech Showcase™ is an important platform for connecting resources and driving innovation during the JPM Healthcare Conference week. AsGlobal Investor Conference for Leading Private and Micro-Mid Cap Biotech Companies,Biotech Showcase™ offers companies the opportunity for in-depth one-on-one interactions with investors and biopharmaceutical executives, with over 3,200 professionals and 1,200 investors expected to participate.

As a representative company in the AI pharmaceuticals field, "MindRank" focuses on empowering innovative drug research and development with a world-leading AI pharmaceuticals platform, accelerating the availability of better drugs for the public. Currently, inAn Industrial-Grade One-Stop AI Pharmaceutical Platform Centered on Molecule Pro™Driven by this, the team is steadily advancing the R&D of new drug pipelines in the fields of metabolism and oncology, and has launched the first self-developed GLP-1RA small molecule oral drug.MDR-001 has entered Phase IIb clinical research,Multiple potential best-in-class or first-in-class projects are in the IND-Enabling stage. Meanwhile, MindRank has recently launchedAI-empowered molecular glue rational design platform and ADME/T property prediction software,Its potential has been validated in multiple internal projects and collaborations with listed pharmaceutical companies, significantly accelerating the R&D process of multimodal drugs such as small molecules, molecular glues, and PROTACs.

If you wish to learn more「MindRank」Innovative Pipeline and Business Development, Welcome via PartneringONE^®Contact us via the collaboration system or email bd@mindrank.ai. We look forward to expanding new collaborations and partnerships during JPM Week.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high clinical value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018-2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the cut. In 2024, it was included in Fortune magazine's IMPACT list as one of "China's most socially influential startups."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai